A review of SSRIs and SNRIs in neuropathic pain

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 17, 2010, Pages 2813-2825

  Lee, Yee Chi ^a   Chen, Phoon Ping ^a  

^a NORTH DISTRICT HOSPITAL   (Hong Kong)

Author keywords

Fibromyalgia; Neuropathic pain; Selective serotonin reuptake inhibitor; Serotonin noradrenaline reuptake inhibitors; SNRI; SSRI

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; AMITRIPTYLINE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; DESIPRAMINE; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; MILNACIPRAN; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; NORFLUOXETINE; NORSERTRALINE; PAROXETINE; PHENYTOIN; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; WARFARIN;

BRADYCARDIA; CHILL; CONSTIPATION; DEPRESSION; DIABETIC NEUROPATHY; DRUG FATALITY; DRUG SENSITIZATION; DRUG WITHDRAWAL; FACE PAIN; FATIGUE; FIBROMYALGIA; GASTROINTESTINAL DISEASE; GENETIC TRANSCRIPTION; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERSENSITIVITY; HYPERTENSION; HYPONATREMIA; LIVER TOXICITY; MAJOR DEPRESSION; MALAISE; MEDLINE; MYALGIA; NAUSEA; NEGATIVE FEEDBACK; NEUROPATHIC PAIN; NOCICEPTION; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PERIPHERAL NERVE INJURY; PERIPHERAL NEUROPATHY; PHENOTYPE; POLYNEUROPATHY; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SEROTONIN SYNDROME; SEROTONINERGIC NERVE CELL; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SWEATING; SYNCOPE; THORAX PAIN; VOMITING; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; DIABETIC NEUROPATHIES; FIBROMYALGIA; HUMANS; NEURALGIA; POLYNEUROPATHIES; SEROTONIN UPTAKE INHIBITORS;

EID: 78149461246     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.507192     Document Type: Review

References (93)

1. McQuay HJ, Tramer M, Nye BA, et al. A systematic review of antidepressants in neuropathic pain. Pain 1996;68:217-27
2. Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005;96:399-409
3. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
4. Loeser JD, Treede RD. The Kyoto protocol of IASP Basic Pain Terminology. Pain 2008;137:473-7
5. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999;353:1959-64
6. Scholz J, Woolf CJ. Can we conquer pain? Nat Neurosci 2002;5:1062-7
7. Basbaum AI, Woolf CJ. Pain. Curr Biol 1999;9:R429-31
8. Woolf CJ. Pain: moving from symptom control towards mechanism-specific pharmacologic management. Ann Intern Med 2004;140:441-51
9. Fields HL, Heinricher M, Mason P. Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci 1991;14:219-45
10. Millan MJ. Descending control of pain. Prog Neurobiol 2002;66:355-474
11. Fields HL, Basbaum AI. Brainstem control of spinal pain transmission neurons. Annu Rev Physiol 1978;40:217-48
12. Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 1984;7:309-38
13. Zhao ZQ, Chiechio S, Sun YG, et al. Mice lacking central serotonergic neurons show enhanced inflammatory pain and an impaired analgesic response to antidepressant drugs. J Neurosci 2007;27:6045-53
14. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review. Pain Med 2000;1:310-16
15. Sugimoto T, Bennett GJ, Kajander KC. Transsynaptic degeneration in the superficial dorsal horn after sciatic nerve injury: effects of a chronic constriction injury, transection, and strychnine. Pain 1990;42:205-13
16. Azkue JJ, Zimmermann M, Hsieh TF, Herdegen T. Peripheral nerve insult induces NMDA receptor-mediated, delayed degeneration in spinal neurons. Eur J Neurosci 1998;10:2204-6
17. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000;288:1765-9
18. Scholz J, Broom DC, Youn DH, et al. Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury. J Neurosci 2005;25:7317-23
19. Suzuki R, Rahman W, Rygh LJ, et al. Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin. Pain 2005;117:292-303
20. Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary descending facilitation. Trends Neurosci 2002;25:319-25
21. Baldessarini RJ. Drug therapy of depression and anxiety disorders. In: Brunton LL, Lazo JS, Parker KL, editors, Goodman and Gilmans the pharmacological basis of therapeutics. 11th edition. McGraw-Hill, Hong Kong; 2006. p. 429-59
22. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999;19:467-89
23. David DJ, Bourin M, Jego G, et al. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. Br J Pharmacol 2003;140:1128-36
24. Moret C, Charveron M, Finberg JP, et al. Biochemical profile of milnacipran (F 2207), 1-phenyl-1-diethylaminocarbonyl- 2-aminomethyl- cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 1985;24:1211-19
25. Muth EA, Moyer JA, Haskins JT, et al. Biochemical, neurophysiological and behavioural effects of WY-45, 233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991;23:191-3
26. Pae CU. Desvenlafaxine: a new antidepressant or just another one? Expert Opin Pharmacother 2009;10:875-87
27. Glynn C, Dawson D, Sanders R. A double-blind comparison between epidural morphine and epidural clonidine in patients with chronic non-cancer pain. Pain 1988;34:123-8
28. Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden AM. Epidural epinephrine and clonidine: segmental analgesia and effects on different pain modalities. Anesthesiology 1997;87:785-94
29. Deffois A, Fage D, Carter C. Inhibition of synaptosomal veratridine-induced sodium influx by antidepressants and neuroleptics used in chronic pain. Neurosci Lett 1996;220 117-20
30. Khalifa M, Daleau P, Turgeon J. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 1999;291:280-4
31. Abdi S, Lee DH, Chung JM. The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesth Analg 1998;87:1360-6
32. Sudoh Y, Cahoon EE, Gerner P, Wang GK. Tricyclic antidepressants as long-acting local anesthetics. Pain 2003;103:49-55
33. DeVane CL, Nemeroff CB. Psychotropic drug interactions. Econ Neurosci 2000;2:55-75
34. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:203-20
35. Hunziker ME, Suehs BT, Bettinger TL, Crismon ML. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther 2005;27:1126-43
36. Puozzo C, Leonard BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 1999;11:15-27
37. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-20
38. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 2003;31:1142-50
39. Spina E, Santoro V, DArrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008;30:1206-27
40. Sindrup SH, Gram LF, Brosen K, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990;42:135-44
41. Sindrup SH, Bjerre U, Dejgaard A, et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992;52:547-52
42. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-6
43. Harrsion SD, Glover L, Feinmann C, et al. A comparison of antidepressant medication alone and in conjunction with cognitive behavioral therapy for chronic idiopathic facial pain. Proceedings of the 8th world congress on pain: progress in pain research and management. Volume 8. In: Jensen TS, Turner JA, Wiesenfeld-Hallin Z, editors, IASP Press, Seattle; 1997. p. 663-72
44. Otto M, Bach FW, Jensen TS, et al. Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. Pain 2009;139:275-83
45. Rowbotham MC, Reisner LA, Davies PS, Fields HL. Treatment response in antidepressant-naive postherpetic neuralgia patients: double-blind, randomized trial. J Pain 2005;6:741-6
46. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain [review]. Cochrane Database Syst Rev 2007;4:CD005454
47. Malemud CJ. Focus on pain mechanisms and pharmacotherapy in the treatment of fibromyalgia syndrome. Clin Exp Rheumotol 2009;27(5 Suppl 56):S86-91
48. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994;23:255-9
49. Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39:1852-9
50. Arnold LM, Hess EV, Hydson JI, et al. A randomized, placebo-controlled, double-blind flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002;112:191-7
51. Norregarrd J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995;61:445-9
52. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia - a randomized double-blind, placebo-controlled study. Eur J Pain 2000;4:27-35
53. Patkar AA, Masand PS, Krulewicz S, et al. A randomized, controlled trial of controlled release paroxetine in fibromyalgia. Am J Med 2007;120:448-54
54. Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants. JAMA 2009;301:198-209
55. Raskin J, Pritchett YL, Wang F, et al. A double-blind randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-56
56. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-18
57. Wernicke JF, Pritchett YL, Dsouza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67:1411-20
58. Lunn MPT, Hughes RAC, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain [review]. Cochrane Database Syst Rev 2009;4:CD007115
59. Wernicke JF, Wang F, Pritchett YL, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med 2007;8:503-13
60. Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Disord 2001;3:53-62
61. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004;110:697-706
62. Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003;60:1284-9
63. Tasmuth T, Hartel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 2002;6:17-24
64. Reuben SS, Makari-Judson G, Lurie SD. Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomy pain syndrome. J Pain Symptom Manag 2004;27:133-9
65. Fava M, Mulroy R, Alpert J, et al. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 1997;154:1760-2
66. Forssell H, Tasmuth T, Tenovuo O, et al. Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. J Orofac Pain 2004;18:131-7
67. Yucel A, Ozyalcin S, Koknel Talu G, et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. Eur J Pain 2005;9:407-16
68. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-84
69. Arnold LM, Rosen A, Pritchett YL, et al. A randomized double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15
70. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-44
71. Mease P, Arnold LM, Bennett R, et al. Fibromyalgia syndrome. J Rheumatol 2007;34:1415-25
72. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32:1977-85
73. Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004
74. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36:398-409
75. Hubbard R, Farrington P, Smith C, et al. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 2003;158:77-84
76. Pacher P, Ungvari Z. Selective serotonin-reuptake inhibitor antidepressants increase the risk of falls and hip fractures in elderly people by inhibiting cardiovascular ion channels. Med Hypotheses 2001;57:469-71
77. Rodriguez de la Torre B, Dreher J, Malevany I, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin inhibitors in depressed patients. Ther Drug Monit 2001;23:435-40
78. Cherin P, Colvez A, Deville de Periere G, Sereni D. Risk of syncope in the elderly and consumption of drugs: a case-control study. J Clin Epidemiol 1997;50:313-20
79. Montgomery SA. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr 2008;13(Suppl 11):27-33
80. Ray WA, Meredith S, Thapa PB, et al. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004;75:234-41
81. Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother 2006;40:1618-22
82. Stovall R, Brahm NC, Crosby KM. Recurrent episodes of serotonin-reuptake inhibitor hyponatremia in an elderly patient. Consult Pharm 2009;24:765-8
83. Romero S, Pintor L, Serra M, et al. Syndrome of inappropriate secretion of antidiuretic hormone due to citalopram and venlafaxine. Gen Hosp Psychiatry 2007;29:81-4
84. Moller HJ, Baldwin DS, Goodwin G, et al. Do SSRI or antidepressants in general increase suicidality? WPA Sectionon harmacopsychiatry. Consensus statement. Eur Arch Psychiatry Clin Neurosci 2008;258:3-23
85. Hawton K, Bergen H, Simkin S, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry 2010;196:354-8
86. Launiainen T, Rasanen I, Vuori E, Ojanpera I. Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Int J Legal Med 2010. [Epub ahead of print]
87. Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf 2008;7:587-96
88. Wenzel RG, Tepper S, Korab WE, Freitag F. Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDAs alert warranted? Ann Pharmacother 2008;42:1692-6
89. Hanje AJ, Pell LJ, Votolato NA, et al. Case report: fulminant hepatic failure involving duloxetine hydrochloride. Clin Gastroenterol Hepatol 2006;47:912-17
90. McIntyre RS, Panjwani ZD, Nguyen HT, et al. The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol 2008;4:281-5
91. Tuccori M, Testi A, Antonioli L, et al. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy. Clin Ther 2009;31:1426-53
92. Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry 1998;5:293-306
93. Schatzberg AF, Haddad P, Kaplan EM, et al. Serotonin reuptake discontinuation syndrome: a hypothetical definition. Discontinuation consensus panel. J Clin Psychiatry 1997;58(Suppl 7):5-10